Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors
- Oops!Something went wrong.Please try again later.
- AGEN
See more from Benzinga
Bristol Myers Unveils More Mavacamten Data To Backup Case For Heart Drug
Pfizer-Bristol Myers' Eliquis Flops In Post-Heart Surgery Trial
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.